Search for: "Purdue Pharma L.P."
Results 81 - 100
of 124
Sorted by Relevance
|
Sort by Date
10 Dec 2019, 3:52 am
” At the Daily Caller, Kevin Daley reports that the justices “declined to grant a bold and unusual request … in a case involving Arizona’s lawsuit against Purdue Pharma L.P. and the billionaire Sackler family for their complicity in the opioid crisis. [read post]
5 May 2017, 9:28 am
Purdue Pharma L.P., 211 F.Supp.3d 1058 (N.D. [read post]
8 Mar 2023, 2:51 pm
Cir. 1996); see also Purdue Pharma L.P. v. [read post]
5 Nov 2018, 5:51 am
Purdue Pharma L.P., et al. [read post]
2 Jun 2023, 12:30 pm
Purdue Pharma L.P. and its owners, the Sackler family, made a mint selling OxyContin as a non-addictive pain reliever. [read post]
24 Jun 2010, 5:00 am
Almost from the day this blog was founded, we’ve been arguing that class actions have no place in prescription medical product liability litigation. [read post]
29 Oct 2013, 9:55 am
., Purdue Pharma L.P. v. [read post]
16 Jan 2017, 5:44 pm
, No. 16-296 (OxyContin patent – when is an element ‘inherently’ disclosed by the prior art for anticipation purposes) Obviousness: Purdue Pharma L.P. v. [read post]
14 Nov 2016, 9:16 am
, No. 16-296 (OxyContin patent – when is an element ‘inherently’ disclosed by the prior art for anticipation purposes) Obviousness: Purdue Pharma L.P. v. [read post]
8 Feb 2017, 3:09 am
, No. 16-296 (OxyContin patent – when is an element ‘inherently’ disclosed by the prior art for anticipation purposes) Obviousness: Purdue Pharma L.P. v. [read post]
13 Sep 2023, 1:57 am
Purdue Pharma L.P., et al. [read post]
5 May 2009, 5:00 am
Purdue Pharma, L.P., 292 F. [read post]
2 Apr 2024, 9:05 pm
Purdue Pharma L.P., No. 23-124 (U.S. [read post]
28 Sep 2016, 8:39 am
, No. 16-296 (OxyContin patent – when is an element ‘inherently’ disclosed by the prior art for anticipation purposes) Obviousness: Purdue Pharma L.P. v. [read post]
23 Aug 2007, 8:06 am
Purdue Pharma, L.P., 295 F.Supp.2d 693, 705 (E.D. [read post]
13 Oct 2016, 6:50 am
, No. 16-296 (OxyContin patent – when is an element ‘inherently’ disclosed by the prior art for anticipation purposes) Obviousness: Purdue Pharma L.P. v. [read post]
10 Feb 2015, 1:01 pm
Purdue Pharma, L.P., 166 F.Supp.2d 546, 551-552 (E.D. [read post]
3 Jan 2014, 6:56 pm
” Purdue Pharma L.P. v. [read post]
24 Feb 2011, 1:49 pm
As our readers certainly know, the learned intermediary rule holds that prescription medical product warnings are to be directed to prescribing physicians rather than to end user patients. [read post]
15 Sep 2011, 5:00 am
A reader recently recommended that we take a look at Rounds v. [read post]